Cover Image

Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer

Gabriel Tremblay,1 Christopher Livings,2 Lydia Crowe,2 Venediktos Kapetanakis,2 Andrew Briggs3 1Global Health Economics and Health Technology Assessment, Eisai Inc., Woodcliff Lake, NJ, USA; 2Health Economics, Decision Resources Group, Bicester, Oxfordshire, 3Health Economics and Health Technology A...

Full description

Saved in:

Bibliographic Details
Main Authors:	Tremblay G (Author), Livings C (Author), Crowe L (Author), Kapetanakis V (Author), Briggs A (Author)
Format:	Book
Published:	Dove Medical Press, 2016-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pharmacoeconomic effectiveness of lenvatinib in patients with differentiated radioiodine-resistant thyroid cancer
by: S. K. Zyryanov, et al.
Published: (2018)

Population pharmacokinetic‐pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC)
by: Oneeb Majid, et al.
Published: (2024)

mutations and aggressive histopathologic characteristics of radioiodine-refractory papillary thyroid cancer
by: Ju Yeon Pyo, et al.
Published: (2024)

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
by: Bo Shi, et al.
Published: (2022)

Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: Systematic review and network meta-analysis
by: Xiaoyu Ji, et al.
Published: (2022)

PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2016)

That's not Metastatic Thyroid Cancer: Patterns of Non-malignant Radioiodine Uptake
by: Daniella F Pinho
Published: (2017)

APOPTOSIS ROLE IN FORMING RADIOIODINE RESISTANCE IN DIFFERENTIATED THYROID CANCER
by: K.A. GARIPOV, et al.
Published: (2020)

In Silico Screening and Validation of PDGFRA Inhibitors Enhancing Radioiodine Sensitivity in Thyroid Cancer
by: Xuefei Yu, et al.
Published: (2022)

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives
by: Costa R, et al.
Published: (2016)

Identification of an Autophagy-Related Signature Predicting Overall Survival for Papillary Thyroid Carcinoma
by: Gang Hu, et al.
Published: (2020)

RADIOIODINE THERAPY OF PAPILLARY THYROID CANCER, COMPLICATED BY A RADIAL MYELITIS. CLINICAL CASE
by: L. M. Farkhutdinova
Published: (2018)

Bevacizumab improves overall survival in platinum refractory ovarian cancer patients: A retrospective study
by: Kenro Chikazawa, et al.
Published: (2018)

Profile of salivary gland flow dysfunctions in patients with differentiated thyroid carcinoma submitted to radioiodine therapy
by: Anna Clara Fontes Vieira, et al.
Published: (2015)

Differentiated Thyroid Cancer in Adolescents: Single Center Experience and Considerations for Surgical Management and Radioiodine Treatment
by: Costanza Chiapponi, et al.
Published: (2023)

Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity
by: Bart Heeg, et al.
Published: (2023)

Effects of radioiodine therapy on fertility indicators among men with differentiated thyroid cancer: A cohort study
by: Salman Soltani, et al.
Published: (2023)

Preliminary study on the efficacy of xerostomia treatment with sialocentesis targeting thyroid disease patients given radioiodine therapy
by: Euy-Hyun Kim, et al.
Published: (2019)

Corrigendum: Overall Survival Prediction of Advanced Cancer Patients by Selection of the Most Significant Baseline Serum Biomarker Combination
by: Daniel Deme, et al.
Published: (2022)

Influence of Lenvatinib on the Functional Reprogramming of Peripheral Myeloid Cells in the Context of Non-Medullary Thyroid Carcinoma
by: Chunying Peng, et al.
Published: (2023)

Systemic Immune-Inflammation Index and Systemic Inflammation Response Index Predict the Response to Radioiodine Therapy for Differentiated Thyroid Cancer
by: Wang Y, et al.
Published: (2024)

Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons
by: Tremblay G, et al.
Published: (2019)

The Safety of Radioiodine Therapy for Women of Reproductive Age
by: Aisyah Elliyanti
Published: (2019)

Review of epidemiological and clinical characteristics and overall survival.
by: Helder Ferreira, et al.
Published: (2014)

Repurposing Lenvatinib as A Potential Therapeutic Agent against Thyroid Eye Disease by Suppressing Adipogenesis in Orbital Adipose Tissues
by: Lu Cheng, et al.
Published: (2022)

Fucoidan attenuates radioiodine-induced salivary gland dysfunction in mice
by: Young-Mo Kim, et al.
Published: (2019)

Improved estimation of overall survival and progression-free survival for state transition modeling
by: Peter C Wigfield, et al.
Published: (2023)

Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework
by: Phyllis Chan, et al.
Published: (2021)

Nomograms to predict overall survival for patients with endometrial carcinosarcoma
by: Christos Iavazzo, et al.
Published: (2023)

Bayesian forecasting of tumor size metrics and overall survival
by: Sreenath M. Krishnan, et al.
Published: (2022)

Effects of three flavonoids on the metabolism of lenvatinib
by: Jinzhao Yang, et al.
Published: (2024)

Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient
by: S. Morelli, et al.
Published: (2017)

Establishing nomograms for predicting disease-free survival and overall survival in patients with breast cancer
by: Ling Zhou, et al.
Published: (2024)

Test of association: which one is the most appropriate for my study?
by: David Alejandro Gonzalez-Chica, et al.
Published: (2015)

JAK inhibitors: an evidence-based choice of the most appropriate molecule
by: Luca Antonioli, et al.
Published: (2024)

Advanced Cervical Cancer: Leveraging the Historical Threshold of Overall Survival
by: Eduardo Paulino, et al.
Published: (2021)

Identification of key gene signatures for the overall survival of ovarian cancer
by: Akash Pawar, et al.
Published: (2022)

Palmoplantar erythrodysesthesia: An unusual side effect of lenvatinib
by: Niraj Virendrabhai Dhinoja, et al.
Published: (2024)

Lenvatinib and pembrolizumab in patients with advanced uterine cancer
by: A. G. Kedrova, et al.
Published: (2021)

Lenvatinib resistance mechanism and potential ways to conquer
by: Wentao Bo, et al.
Published: (2023)